Epstein-Barr virus and non-Hodgkin lymphoma: A study in Kermanshah, Iran

Ali Shahriari-Ahmadi¹, Babak Izadi², Masoud Sadeghi^{3, 4,} , Mehrdad Payandeh² and Edris Sadeghi^{3, 4}

¹Rasool-Akram Hospital, Oncology and Hematology ward, Iran University of Medical Sciences, Tehran, Iran

²Department of Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

³Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

⁴Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Cite this paper:
Ali Shahriari-Ahmadi, Babak Izadi, Masoud Sadeghi, Mehrdad Payandeh and Edris Sadeghi. Epstein-Barr virus and non-Hodgkin lymphoma: A study in Kermanshah, Iran. American Journal of Cancer Prevention. 2015; 3(5):91-93. doi: 10.12691/ajcp-3-5-4

Abstract

Background: Epstein-Barr virus (EBV) infection is highly associated with specific subtypes of malignant lymphoma such as types of aggressive non-Hodgkin lymphoma (NHL). We aimed to evaluate the prevalence of EBV in NHL and its association with clinical parameters. Patients and Methods: twenty cases entered to our study. After re-blocking of previous paraffin embedded specimens, new slides were prepared and DNA was extracted. DNA contents were confirmed by spectrophotometery. Then PCR assay was used for total DNA and its product evaluate for presence of EBV by electrophoresis. Results: The mean age at diagnosis for all patients was 45±13 years (range, 28-73) years that 12 patients (60%) were male. Based on histopathology reports, 13 patients (65%) had immunoblastic Lymphoma, 5 (25%) had burkitt Lymphoma and 2 (10%) had LL (lymphoblastic Lymphoma). Conclusion: There is no EBV infection in NHL patients with LLs and percent of EBV infection in our study is lower than other studies.

Keywords:
EBV infection NHL Burkitt lymphoma

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	McGeoch DJ, Cook S, Dolan A, Jamieson FE, Telford EA. Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses. J Mol Biol. 1995. 247 (3): 443-58.
[2]	Hjalgrim H, Friborg J, Melbye M. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007. Chapter 53. The epidemiology of EBV and its association with malignant disease.
[3]	Mitarnun W, Suwiwat S, Pradutkanchana J. Epstein-Barr virus-associated extranodal non-Hodgkin's lymphoma of the sinonasal tract andnasopharynx in Thailand. Asian Pac J Cancer Prev. 2006. 7 (1): 91-4.
[4]	Heslop HE. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program. 2005: 260-6.
[5]	Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF. HIV-associated lymphomas and gamma-herpesviruses. Blood. 2009. 113 (6): 1213-24.
[6]	Olweny CL, Atine I, Kaddu-Mukasa A, Owor R, Andersson-Anvret M, Klein G, et al. Epstein-Barr virus genome studies in Burkitt's and non-Burkitt's lymphomas in Uganda. J Natl Cancer Inst. 1977. 58 (5): 1191-6.
[7]	Geser A, Lenoir GM, Anvret M, Bornkamm G, Klein G, Williams EH, et al. Epstein-Barr virus markers in a series of Burkitt's lymphomas from the West Nile District, Uganda. Eur J Cancer Clin Oncol. 1983. 19 (10): 1393-404.
[8]	Cool CD, Bitter MA. The malignant lymphomas of Kenya: morphology, immunophenotype, and frequency of Epstein-Barr virus in 73 cases. Hum Pathol. 1997. 28 (9): 1026-33.
[9]	Teras LR, Rollison DE, Pawlita M, Michel A, Brozy J, de Sanjose S, et al. Epstein-Barr virus and risk of non-Hodgkin lymphoma in the cancer prevention study-II and a meta-analysis of serologic studies. Int J Cancer. 2015. 136 (1): 108-16.
[10]	Mitarnun W, Pradutkanchana J, Takao S, Saechan V, Suwiwat S, Ishida T. Epstein-barr virus-associated non-Hodgkin's lymphoma of B-cell origin, Hodgkin's disease, acute leukemia, and systemic lupus erythematosus: a serologic and molecular analysis. J Med Assoc Thai. 2002. 85 (5): 552-9.
[11]	Chabay PA, De Matteo EN, Aversa L, Maglio S, Grinstein S, Preciado MV. Assessment of Epstein-Barr virus association with pediatric non-hodgkin lymphoma in immunocompetent and in immunocompromised patients in Argentina. Arch Pathol Lab Med. 2002. 126 (3): 331-5.
[12]	Kasprzak A, Spachacz R, Wachowiak J, Stefanska K, Zabel M. Epstein-Barr virus (EBV) infection in B-cell non-Hodgkin's lymphomas in children: virus latency and its correlation with CD21 and CD23 molecules. Folia Histochem Cytobiol. 2007. 45 (3): 169-79.
[13]	Ishtiaq S, Hassan U, Mushtaq S, Akhtar N. Determination of frequency of epstein-barr virus in non- Hodgkin lymphomas Using EBV latent membrane protein 1 (EBV-LMP1) immunohistochemical staining. Asian Pac J Cancer Prev. 2013. 14 (6): 3963-7.
[14]	Brady G, MacArthur GJ, Farrell PJ. Epstein-Barr virus and Burkitt lymphoma. J Clin Pathol. 2007. 60 (12): 1397-402.
[15]	Tumwine LK, Orem J, Kerchan P, Byarugaba W, Pileri SA. EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda. Infect Agent Cancer. 2010. 5: 12.
[16]	Raphael MM, Audouin J, Lamine M, Delecluse HJ, Vuillaume M, Lenoir GM, et al. Immunophenotypic and genotypic analysis of acquired immunodeficiency syndrome-related non Hodgkin's lymphomas. Correlation with histologic features in 36 cases. French Study Group ofPathology for HIV-Associated Tumors. Am J Clin Pathol. 1994. 101 (6): 773-82.
[17]	Flavell KJ, Murray PG. Hodgkin's disease and the Epstein-Barr virus. Mol Pathol. 2000. 53 (5): 262-9.